Cancer

1. Labelle M, Hynes RO. The Initial Hours of Metastasis: The Importance of Cooperative Host–Tumor Cell Interactions during Hematogenous Dissemination. Cancer Discov. 2012 Dec;2(12):1091-9. doi: 10.1158/2159-8290.CD-12-0329. Epub 2012 Nov 19. PMCID: PMC3540992
2. Reticker-Flynn, N.E., Malta, D.F.B., Winslow, M.M., Lamar, J.M., Xu, M.J., Underhill, G.H., Hynes, R.O., Jacks, T.E., and Bhatia, S.N. (2012). A combinatorial extracellular matrix platform identifies cell-extracellular matrix interactions that correlate with metastasis. Nature Communications 3, 1122. PMID:23047680
3. Lamar, JM, Stern, P., Liu, H., Schindler, JW, Jiang, Z. and Hynes, RO. (2012). The Hippo pathway target, YAP, promotes metastasis through its TEAD interaction domain. Proc. Natl. Acad. Sci. USA, [Epub ahead of print, Aug 13, 2012]. PMCID:PMC3443162
4. Naba, A., Clauser, K.R., Hoersch, S., Liu, H., Carr, S.A. and Hynes, R.O. (2012). The matrisome: in silico definition and in vivo characterization by proteomics of normal and tumor extracellular matrices. Mol. Cell Proteomics. 11(4): M111.014647. Published online Dec. 9, 2011. PMCID: PMC3322572
5. Hynes, R.O. (2011). Metastatic cells will take any help they can get. Cancer Cell 20: 689-690. doi:10.1016/j.ccr.2011.11.022. PMCID: PMC3462586.
6. Labelle M., Begum S., and Hynes R.O. (2011). Direct Signaling between Platelets and Cancer Cells Induces an Epithelial-Mesenchymal-Like Transition and Promotes Metastasis. Cancer Cell 20: 576-590. PMCID: PMC3487108. doi:10.1016/j.ccr.2011.09.009
7. Liu, H., Ong, S-E., Badu-Nkansah, K., Schindler, J., White, F.M. and Hynes, R.O. (2011). CUB-domain-containing protein 1 (CDCP1) activates Src to promote melanoma metastasis. Proc. Natl. Acad. Sci. USA, 108:1379-1384; published online ahead of print January 10, 2011. doi:10.1073/pnas.1017228108 PMCID: PMC3029734
8. Xu, L., Begum, S., Barry, M. Crowley, D. and Hynes, R.O. (2010). GPR56 plays complex roles in endogenous cancer progression. Clin. Exp. Metastasis 27:241-249. PMCID: PMC3065979
9. Sobolev, O., Stern, P., Lacy-Hulbert, A., Hynes, R. O. (2009). Natural killer cells use selectins for suppression of subcutaneous tumors. Cancer Res. 69:2531-2539. (Epub ahead of print, Mar 3). PMCID: PMC2694740
10. Hori, Y., Stern, P., Hynes, R.O. and Irvine, D.J. (2009). Engulfing tumors with synthetic extracellular matrices for tumor immunotherapy and analysis of local anti-tumor immune responses. Biomaterials 30:6757-6787. PMCID: PMC2788234
11. Xu, L., Shen, S., Hoshida, Y., Subramanian, A., Ross, K., Brunet, J.P., Ramaswamy, S., Mesirov, J.P. and Hynes, R.O. (2008). Gene expression changes in an animal melanoma model correlate with aggressiveness of human melanoma metastases. Mol Cancer Res. 6:760-769. PMCID: PMC2756991
12. Wong, S.Y., Crowley, D, Bronson, R.T. and Hynes, R.O. (2008). Analyses of the Role of Endogenous SPARC in mouse models of prostate and breast cancer. Clin. Exp. Metastasis 25: 109-118. PMCID: PMC3252392
13. McCarty, J.H., Barry, M., Crowley, D., Bronson, R.T., Lacy-Hulbert, A. and Hynes, R.O. (2008). Genetic ablation of av integrins in epithelial cells of the eyelid skin and conjunctiva leads to squamous cell carcinoma. Am. J. Path. 172:1740-1747. PMCID: PMC2408432
14. Wong, S.Y. and Hynes, R.O. (2007).  Tumor-lymphatic interactions in an activated stromal microenvironment.     J. Cell Biochem. 101: 840-850.
15. Xu, L. and Hynes, R.O. (2007). GPR56 and TG2: possible roles in suppression of tumor growth by the microenvironment. Cell Cycle. 6(2):160-5. http://dx.doi.org.ezproxyberklee.flo.org/10.4161/cc.6.2.3760
16. Wong, S.Y., Haack, H., Kissil, J.L., Barry, M., Bronson, R.T., Shen, S.S., Whittaker, C.A., Crowley, D, and Hynes, R.O. (2007). Protein 4.1B suppresses prostate cancer progression and metastasis. Proc. Natl. Acad. Sci. USA 104: 12784-12789. PMCID: PMC1924789
17. Xu, L., Begum, S., Hearn, J.D. and Hynes, R. O.  (2006).  GPR56, an atypical G protein-coupled receptor, binds tissue transglutaminase, TG2, and inhibits melanoma tumor growth and metastasis. Proc. Natl. Acad. Sci. USA. 103: 9023-9028. PMCID: PMC1474142
18. Wong, S.Y. and Hynes, R.O. (2006). Lymphatic or hematogenous dissemination: how does a metastatic tumor cell decide?  Cell Cycle 5: 812-817. PMCID: PMC1459485
19. Taverna, D., Crowley, D., Connolly, M., Bronson, R.T. and Hynes, R.O.  (2005). A direct test of potential roles for b3 and b5 integrins in growth and metastasis of murine mammary carcinomas.  Cancer Res. 65: 10324-10329. doi: 10.1158/0008-5472.CAN-04-4098
20. Wong, S.Y., Haack, H., Crowley, D., Barry, M., Bronson, R.T. and Hynes. R.O. (2005). Tumor-secreted VEGF-C is necessary for prostate cancer lymphangiogenesis, but lymphangiogenesis is unnecessary for lymph node metastasis.  Cancer Res. 65: 9789-9798.
21. Astrof, S., Crowley, D., George, E.L., Fukuda, T., Sekiguchi, K., Hanahan, D. and Hynes, R.O. (2004).  Direct test of potential roles of EIIIA and EIIIB alternatively spliced segments of fibronectin in physiological and tumor angiogenesis.  Mol. Cell. Biol. 24: 8662-8670. PMCID: PMC516752
22. Taverna, D., Moher, H., Crowley, D., Borsig.L., Varki, A. and Hynes, R.O. (2004). Increased primary tumor growth in mice null for β3- or β3/β5-integrins or selectins. Proc. Natl. Acad. Sci. USA 101: 763-768. PMCID: PMC321755
    
23. Hynes, R.O. (2003). Metastatic potential: generic predisposition of the primary tumor or rare, highly metastatic variants—or both? Cell 113: 1-3.
    
24. Borsig, L., Wong, R., Hynes, R.O., Varki, N.M. and Varki, A. (2002). Synergistic effect of L- and P-selectin in facilitating tumor metastasis in a syngeneic system involving non-mucin ligands - further evidence for selectin inhibition as a mode of heparin action. Proc. Natl. Acad. Sci. USA 99: 2193-2198. PMCID: PMC122341
    
25. Reynolds, L., Wyder, L., Lively, J.C., Taverna, D., Robinson, S.D., Huang, X., Sheppard, D, Hart, I., Hynes, R.O. and Hodivala-Dilke, K. (2002). Enhanced pathological angiogenesis in mice lacking β3-integrin or β3- and β5-integrins. Nature Medicine 8: 27-34.
    
26. Taverna, D. and Hynes, R.O. (2001). Reduced blood vessel formation and tumor growth in α5 integrin-negative teratocarcinomas and embryoid bodies. Cancer Res. 61:5255-5261.
    
27. Lawler, J., Miao, W.M., Duquette, M., Bouck, N., Bronson, R.T. and Hynes, R.O. (2001). Thrombospondin-1 gene expression affects survival and tumor spectrum of p53-deficient mice. Am.J. Path. 159: 1949-1956 PMCID: PMC1867067
    
28. Rodriguez-Manzaneque, J.C., Lane, T.F., Ortega, M.A., Hynes, R.O., Lawler, J. and Iruela-Arispe, M.L. (2001). Thrombospondin-1 suppresses spontaneous tumor growth and angiogenesis and inhibits activation of matrix metalloprotease-9 and mobilisation of VEGF. Proc. Natl. Acad. Sci. USA 98: 12485-12490. PMCID: PMC60080
    
29. Clark, E.A., Golub, T.R., Lander, E. and Hynes, R.O. (2000) Genomic analysis of metastasis reveals an essential role for rhoC. Nature, 406: 532-535.
    
30. Taverna, D., Ullman-Culleré, M., Rayburn, H., Bronson, R.T. and Hynes, R.O. (1998). A test of the role of α5 integrin/fibronectin interactions in tumorigenesis. Cancer Res., 58: 848-853.
    
31. Stellmach, V., Volpert, O.V., Crawford, S.E., Lawler, J., Hynes, R.O. and Bouck, N. (1997) Tumor suppressor genes and angiogenesis: the role of p53 in fibroblasts. Eur. J. Cancer 32A: 2394-2400.
    
32. Hynes, R.O., and Plantefaber, L.C. (1991). Integrin receptors for extracellular matrix and their involvement in oncogenic transformation. In Origins of Human Cancer: A Comprehensive Review (Brugge, J., Curran, T., Harlow, E and McCormick, F.). Plainview, NY: Cold Spring Harbor. pp. 293-307.
    
33. Plantefaber, L.C. and Hynes, R.O. (1989). Changes in integrin receptors on oncogenically transformed cells. Cell 56:281-290.
    
34. Wagner, D.D., Ivatt, R., Destree, A.T. and Hynes, R.O. (1981). Similarities and differences between the fibronectins of normal and transformed hamster cells. J. Biol. Chem. 256:11708-11715.
    
35. Senger D.R., Wirth, D.F., Bryant, C. and Hynes, R.O. (1980). Transformation-specific secreted proteins in "Viral Oncogenes", Cold Spring Harbor Symposia 44:651-657.
    
36. Senger, D.R., Wirth, D.F. and Hynes, R.O. (l980). Transformation-specific secreted phosphoproteins. Nature 286:619-621.
    
37. Senger, D.R., Wirth, D.F. and Hynes, R.O. (1979). Transformed mammalian cells secrete specific proteins and phosphoproteins. Cell 16:885-894.
    
38. Mautner, V.M. and Hynes, R.O. (1977). Surface distribution of LETS protein in relation to the cytoskeleton of normal and transformed fibroblasts. J. Cell Biol. 75:743-768.
    
39. Ali, I.U., Mautner, V.M., Lanza, R.P. and Hynes, R.O. (1977). Restoration of normal morphology, adhesion and cytoskeleton in transformed cells by addition of a transformation-sensitive surface protein. Cell 11:115-126.
    
40. Critchley, D.R., Wyke, J.A. and Hynes, R.O. (1976). Cell surface and metabolic labelling of the proteins of normal and transformed chicken cells. Biochim. Biophys. Acta 436:335-352.
    
41. Hynes, R.O. (1976). Cell surface proteins and malignant transformation. Biochim. Biophys. Acta 458:73-107.
    
42. Hynes, R.O. and Wyke, J.A. (1975). Alterations in surface proteins in chicken cells transformed by temperature-sensitive mutants of Rous sarcoma virus. Virology 64:492-504.
    
43. Hynes, R.O. (1974). Role of surface alterations in cell transformation: the importance of proteases and surface proteins. Cell 1:147-158.
    
44. Hynes, R.O. (1973). Alteration of cell-surface proteins by viral transformation and by proteolysis. Proc. Natl. Acad. Sci. USA 70:3170-3174.